Search Results

1 - 9 of 9 items :

  • "prostate cancer" x
  • Rheumatology x
Clear All
The association between chronic pancreatitis and the iNOS-2087A>G polymorphism

2008; 17 (3):727-31. 26. LEE KM., KANG D., PARK S.K., BERNDT S.I., REDING D., CHATTERJEE N., et al . Nitric oxide synthase gene polymorphisms and prostate cancer risk . Carcinogenesis. 2009; 30 (4):621-5. 27. JOHANNESEN J., POCIOT F., KRISTIANSEN O.P., KARLSEN A.E., NERUP J. No evidence for linkage in the promoter region of the inducible nitric oxide synthase gene (NOS2) in a Danish type 1 diabetes population. Genes Immun. 2000; 1 (6):362-6.

Open access
The Hong Kong Society of Rheumatology Biologics Registry: Updated Report (May 2016)

), prostate cancer (N = 1), stomach cancer (N = 1), cancer of penis (N = 1), gall bladder cancer (N = 1), cancer of urinary bladder (N = 1), cancer of small intestine (N = 1), kidney cancer (N = 1), cancer of ampulla of vater (N = 1), thyroid cancer (N = 1), mandible cancer (N = 1), adenocarcinoma (N = 1), cervical intraepithelial neoplasia (CIN) (N = 1), myeloma (N = 1), myelodysplastic syndrome (N = 1), brain tumor (N = 1), malignant melanoma (N = 1), and renal cell carcinoma (N = 1). Infection Requiring Hospitalization There were 105 episodes of infective

Open access
The Hong Kong Society of Rheumatology Biologics Registry: Updated Report (December 2016)

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Not stated 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Major Adverse Events Reported Neoplasia There were 36 cases of malignant and pre-malignant conditions reported: colon cancer (N=4), breast cancer (N=3), lungcancer (N=3), ovarian cancer (N=3), tongue cancer (N=1), caecum cancer (N=1), intraductal papillary mucinous neoplasm ofpancreas (N=1), rectum cancer (N=1), prostate cancer (N=1), stomach cancer (N=1

Open access
The Hong Kong Society of Rheumatology Biologics Registry: Updated Report (November 2017)

pre-malignant conditions reported: colon cancer (N=4), lung cancer (N=4), rectum cancer (N=4), breast cancer (N=3), ovarian cancer (N=3), tongue cancer (N=1), caecum cancer (N=1), intraductal papillary mucinous neoplasm of pancreas (N=1), prostate cancer (N=1), stomach cancer (N=1), penile cancer (N=1), gall bladder cancer (N=1), cancer of urinary bladder (N=1), cancer of small intestine (N=1), kidney cancer (N=1), cancer of ampulla of vater (N=1), thyroid cancer (N=1), mandible cancer (N=1), adenocarcinoma (N=1), myeloma (N=1), cervical intra-epithelial neoplasia

Open access
The Hong Kong Society of Rheumatology Biologics Registry: Updated Report (May 2018)

0 0 0 0 0 0 0 0 0 0 0 Unknown 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 4 Major Adverse Events Reported 4.1 Neoplasia There were 48 cases of malignant and pre-malignant conditions reported: lung cancer (N = 5), rectum cancer (N = 5), colon cancer (N = 4), breast cancer (N = 3), ovarian cancer (N = 3), lymphoma (N = 2), pulmonary MALT lymphoma (N = 1), tongue cancer (N = 1), caecum cancer (N = 1), intraductal papillary mucinous neoplasm of pancreas (N = 1), prostate cancer (N = 1), stomach cancer

Open access
The Hong Kong Society of Rheumatology Biologics Registry: Updated Report (May 2017)

), intraductal papillary mucinous neoplasm of pancreas (N = 1), prostate cancer (N = 1), stomach cancer (N = 1), penile cancer (N = 1), gall bladder cancer (N = 1), cancer of urinary bladder (N = 1), cancer of small intestine (N = 1), kidney cancer (N = 1), cancer of ampulla of vater (N = 1), thyroid cancer (N = 1), mandible cancer (N = 1), adenocarcinoma (N = 1), cervical intra-epithelial neoplasia (CIN) (N = 1), myeloma (N = 1), myelodysplastic syndrome (N = 1), brain tumor (N = 1), malignant melanoma (N = 1), renal cell carcinoma (N = 1), nasopharyngeal cancer (N = 1), and

Open access
The Hong Kong Society of Rheumatology Biologics Registry: Updated Report (Nov 2018)

), rectum cancer (N=5), colon cancer (N=4), breast cancer (N=4), ovarian cancer (N=4), lymphoma (N=2), nasopharyngeal cancer (N=2), pulmonary MALT lymphoma (N=1), tongue cancer (N=1), caecum cancer (N=1), intraductal papillary mucinous neoplasm of pancreas (N=1), prostate cancer (N=1), stomach cancer (N=1), penile cancer (N=1), gall bladder cancer (N=1), cancer of urinary bladder (N=1), cancer of small intestine (N=1), kidney cancer (N=1), cancer of ampulla of vater (N=1), thyroid cancer (N=1), mandible cancer (N=1), adenocarcinoma (N=1), myeloma (N=1), cervical intra

Open access
VEGF expression in pancreatic cancer and other malignancies: a review of the literature

Z.B., SUN Y.Q., ZHANG C.Q. Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis. Tumour Biol. 2014 Jan; 35 (1):155-60. 39. WOOLLARD D.J., OPESKIN K., COSO S., WU D., BALDWIN M.E., WILLIAMS E.D. Differential expression of VEGF ligands and receptors in prostate cancer. Prostate. 2013 May; 73 (6):563-72. 40. KOPPARAPU P.K., BOORJIAN S.A., ROBINSON B.D., DOWNES M., GUDAS L.J., MONGAN N.P., PERSSON J.L. Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Res. 2013 Jun

Open access
ANA Testing: What should we know about the methods, indication and interpretation?

antibody was first described in 1990s during surveys of ANA in patients with interstitial cystitis and chronic fatigue syndrome.[ 19 , 21 ] Subsequently, it was also reported in a variety of other conditions, including atopic dermatitis, prostate cancer, autoimmune thyroiditis and even healthy subjects.[ 19 , 20 , 22 , 23 ] Figure 1 Dense fine speckle pattern in IIFA Indeed, anti-DFS70 is not infrequent in ANA positive healthy subjects. Watanabe et al. [ 11 ] reported in their study on healthy hospital workers that 11% of their cohort were positive for

Open access